CureVac - Hauptforum WKN: A2P71U ISIN: NL0015436031 Kürzel: CVAC Forum: Aktien User: NeulingImDAX

Wie oben (und im Blog) geschrieben, denke ich, dass das bereits der Fall ist. Die müssen nun sequenziert und ausgewertet werden. Im Klartext: die 59 cases sind nicht mehr der jüngste Stand. Bei weitem nicht. Bleibt aber persönliche Einschätzung.

Also dann sollten wir doch die 111 zusammen bekommen

Dabei den exponentiellen Aufbau der 40.000 nicht außer Acht lassen.

@Jense die Annahmen zum Infektionsverlauf (1,5 cases/1.000/Monat) ist dem ctp zu entnehmen.

Sehr = Der

Noch was zur Entblindung ... Ein Ziel der Verblindung ist das Abwarten des Auftretens ausreichender Zahl an Infektionen aller zu untersuchenden Varianten. Das hat mit der efficacy also nichts zu tun. Diese kann eben nur noch nicht statistisch belastbar ermittelt werden. Die Entblindung soll nach nicht überprüfbaren Aussagen von Phase 3 Probanden aber bereits laufen. Ein Hintergrund ist zumindest in D u.a. auch der Entfall der Impfpriorisierung. Bei 40 k Probanden in 10 Ländern und 2 Zeitzonen auch administrativ herausfordernd. Sehr Bearbeitungsstand der Studienergebnisse ist weiter, als es aus der Pressemitteilung abzuleiten ist.

Ich fasse nochmal zusammen... Wir sind noch in der time line... Finale Ergebnisse und zulassung sollen noch im Juni erfolgen... Laut Azssage einer curevac Sprecherin. Also nix Negatives.... Soweit?!

@Toi jetzt verstehe ich, was du meinst. Zu Punkt 4) Einen direkten Zusammenhang von Entblindung und efficacy >85% ab IAD I kann ich auch nicht erkennen. Aber ich müsste im ctp nachlesen, kann’s mir aber nicht vorstellen. Das kann aber Longie vielleicht aufklären? Vielleicht sprichst du ihn direkt per PN an?

https://www.citizen.org/article/how-to-make-enough-vaccine-for-the-world-in-one-year/

To produce eight billion doses of the NIH-Moderna Covid-19 mRNA vaccine within six months, 55 production lines would be required, as shown in Table 3 below. These 55 production lines can be placed into 14 facilities and would complete a total of 10,175 batches in six months. Out of the 14 facilities, 13 facilities would contain four production lines per facility and the remaining one facility would contain three production lines per facility. The total capital cost required to construct, equip, validate, and start up the 14 facilities, with three or four production lines per facility, for producing eight billion mRNA-1273 vaccine doses is estimated at $3.19 billion.

To produce eight billion doses of the BioNTech Covid-19 mRNA vaccine within six months, 17 production lines and 3,145 batches would be required, as shown in Table 3 below. These 17 production lines can be placed into five facilities, three of these facilities would have three production lines per facility and the remaining two facilities would contain four production lines per facility. The total capital cost required to construct, equip, validate, and start up the five facilities, with three or four production lines per facility, for producing eight billion BNT162b2 vaccine doses is estimated at $985 million.

To produce eight billion doses of the CureVac Covid-19 mRNA vaccine within six months, seven production lines and 1,295 batches would be required, as shown in Table 3 below. These seven production lines can be placed into two facilities; one of these facilities would have three production lines and the other facility would contain four production lines. The total capital cost required to construct, equip, validate, and start up the two facilities with three or four production lines per facility for producing eight billion CVnCoV vaccine doses is estimated at $405.6 million.

Ruudi. Luciman.Annchen. Suggest this will help and I will post the full report later- as this on its own if CVAC comes through will blow Pfizer and Moderna away. (CureVac’s doses might also turn out to be cheaper than the others. Public Citizen, a consumer advocacy organization, released a report Wednesday from researchers at Imperial College London, estimating the costs of producing enough RNA vaccines to provide herd immunity in low- and middle-income countries. Researchers found that iIt would cost $23 billion to make 8 billion doses of Pfizer-BioNTech, $9 billion for Moderna and just $4 billion for CureVac. Last year, the company’s vaccine had promising results when used on animals. By December they had launched their final clinical trial, recruiting 40,000 volunteers in 10 countries in Latin America and Europe. On Wednesday, CureVac indicated that further information about its vaccine trial would arrive by the end of June.)

AS posted earlier- the warning signs are now in place- as if Vietnam with its strict policy of isolation-track trace is seeing a new variant- you can be assured the EU and USA-Israel are light years behind https://www.straitstimes.com/asia/se-asia/vietnam-detects-hybrid-of-covid-19-variant-identified-in-india-and-uk

Wie gesagt war nur ganz grob über den Daumen... Wollte damit nur sagen ich denke die 111 und mehr haben wir erreicht unter den 40k Probanden...

I have viewed the stocktwits link- in all honesty I do not understand it and how the person dervies a figure. Also I have an issue here with Curvac data of last night- for me its been put out in haste to cover the fact that Curevac spokewoman spoke out of turn and it left Curevac with a headache . The media group who published the report on Thursday had to many contradictions in it. Curevac are new as far as company listed on the NSADAQ and they certainly need to learn the listing regulations and relaize they are no longer a private company. It does also beg this question from me- The CEO needs to take a tighter grip and Curvac needs Ingmar on board doing what he dose best and that is leading and explaining everything from the front. I am not negative on what Curevac are doing in the trials- but certainly Curevac need a tighter grip in some areass. Other point- if you read any of the Argentine press- they give the impression from people vaccinated in the trial - that they want the all signing all dancing Curevac vaccine now..